查看購物車
  • Simplified Chinese
  • English
  • Japanese
歐洲基因分型市場預測至 2031 年 - 區域分析 - 按產品類型、技術、應用和最終用戶
市場調查報告書
商品編碼
1666235

歐洲基因分型市場預測至 2031 年 - 區域分析 - 按產品類型、技術、應用和最終用戶

Europe Genotyping Market Forecast to 2031 - Regional Analysis - by Product Type, Technology, Application, and End user
出版日期: | 出版商: The Insight Partners | 英文 156 Pages | 訂單完成後即時交付

價格

2023 年歐洲基因分型市值為 87.299 億美元，預計到 2031 年將達到 438.8343 億美元；預計 2023 年至 2031 年的複合年成長率為 22.4%。

生物技術和製藥行業的技術進步和研發投資的增加推動了歐洲基因分型市場的發展

基因分型市場參與者正致力於增加對旨在推動生物技術進步的計畫的投資，以提供比傳統技術更好的替代方案。

2024 年 1 月，賽默飛世爾科技推出 Axiom PangenomiX Array，為藥物基因體學研究和群體規模疾病研究提供最佳基因覆蓋。此陣列是目前唯一可以在一次測試中運行四種檢測的研究解決方案：SNP 基因分型、完整基因組拷貝數變異檢測、固定拷貝數發現以及血液和 HLA 分型。 2023 年 9 月，Bio-Rad 推出了用於定序、克隆和基因分型的新型 PTC Tempo 48/48 和 PTC Tempo 384 熱循環儀。 PTC Tempo 熱循環儀具有直覺的使用者介面和靈活的連接功能，可簡化協定管理，並具有雲端平台上的監控功能。 2023 年 1 月，Qiagen 收購了 Verogen，後者是一家利用次世代定序 (NGS) 技術推動法醫調查和人類身分識別 (HID) 未來發展的公司。 QIAGEN 和 Verogen 有望共同創造機會，幫助研究人員推進法醫科學，有助於準確識別嫌疑人、尋找失蹤者並為無辜者洗脫罪名。 2022 年 6 月，NRGene 推出了 Soy SNPro，這是一款涵蓋預先設計的 SNP 集的產品，用於各種作物的基因分型（DNA 測試）。 SNPro 是一種現成的完整基因分型解決方案，結合了低密度基因分型和高密度歸因。 2022 年 5 月，NEOGEN 公司和 Gencove 宣布推出 InfiniSEEK，這是一種創新且經濟高效的解決方案，可解決全基因組定序和有針對性的 SNP 分析所涉及的困難。這些技術突破有可能實現小型化、自動化和降低成本。它們還可以幫助提高操作靈活性和多參數測試。所有這些好處都增加了 DNA 定序的用途和便利性，使臨床醫生能夠專注於更高層次的決策，例如透過各種基因分型研究選擇和確定治療目標的優先順序。此外，NGS等DNA定序技術的進步使得定序速度更快、更準確，進而提高了生產效率。因此，日益成長的研究和開發活動以及政府對基因組計畫的資助不斷增加，促進了基因分型市場的進步。

歐洲基因分型市場概況

歐洲基因分型市場分為德國、英國、法國、義大利、西班牙和歐洲其他地區。該地區佔據全球基因分型市場的第二大佔有率，預計在預測期內將實現顯著的複合年成長率。技術進步、DNA定序程序價格降低、遺傳疾病發生率增加以及個人化醫療意識增強等因素都是促進歐洲基因分型市場成長的因素。

歐洲基因分型市場收入及預測（2031 年）（百萬美元）

歐洲基因分型市場細分

歐洲基因分型市場分為產品類型、技術、應用、最終用戶和國家。

根據產品類型，歐洲基因分型市場分為儀器、試劑和試劑盒、生物資訊學和基因分型服務。試劑和試劑盒部分在 2023 年佔據了最大的市場佔有率。

根據技術，歐洲基因分型市場細分為微陣列、毛細管電泳、定序、聚合酶鏈反應 (PCR)、基質輔助雷射解吸/MALDI-TOF 和其他技術。聚合酶鏈反應 (PCR) 領域在 2023 年佔據了最大的市場佔有率。

根據應用，歐洲基因分型市場分為藥物基因組學、診斷和個人化醫療、動物遺傳學、農業生物技術和其他應用。 2023 年，診斷和個人化醫療領域佔據最大的市場佔有率。

就最終用戶而言，歐洲基因分型市場分為製藥和生物製藥公司、診斷和研究實驗室、學術機構和其他最終用戶。 2023 年，製藥和生物製藥公司部門佔據了最大的市場佔有率。

依國家分類，歐洲基因分型市場分為英國、德國、法國、西班牙、義大利和歐洲其他地區。 2023 年，德國佔據歐洲基因分型市場的主導佔有率。

Hoffmann-La Roche Ltd、QIAGEN NV、Merck KGaA、EUROFINS GENOMICS、Thermo Fisher Scientific Inc、BioTek Instruments Inc、Illumina Inc、Danaher Corp、Bio-Rad Laboratories Inc、GE HealthCare Technologies Inc、Standard BioTools Inc、Laboratory Corp of America、Sooratory Corp of。是歐洲基因分型市場的一些領導公司。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 關鍵見解

第3章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 發育基數：
    • 數據三角測量：
    • 國家級資料：

第 4 章：歐洲基因分型市場格局

  • 概述
  • 全球市佔率分析
    • NGS 文庫製備主要參與者的全球市佔率（%）
    • 基因分型領導企業的全球市場佔有率（%）
    • 基因表現領域領導企業的全球市場佔有率（%）

第 5 章：歐洲基因分型市場 - 主要市場動態

  • 市場促進因素：
    • 用於診斷遺傳疾病和罕見疾病
    • 生物技術和製藥行業的技術進步和研發投資不斷增加
  • 市場限制
    • 設備成本高，專業技術人員短缺
  • 市場機會
    • 擴大應用範圍
  • 未來趨勢
    • 個人化醫療日益普及
  • 促進因素和限制因素的影響：

第 6 章：基因分型市場 - 歐洲分析

  • 2021 至 2031 年基因分型市場收入

第 7 章：歐洲基因分型市場分析 - 依產品類型

  • 儀器
  • 試劑和試劑盒
  • 生物資訊學
  • 基因分型服務

第 8 章：歐洲基因分型市場分析 - 按技術

  • 微陣列
  • 毛細管電泳
  • 定序
  • 聚合酶鍊式反應（PCR）
  • 基質輔助雷射解吸/MALDI-TOF
  • 其他技術

第 9 章：歐洲基因分型市場分析 - 按應用

  • 藥物基因組學
  • 診斷及個人化醫療
  • 動物遺傳學
  • 農業生物技術
  • 其他應用

第 10 章：歐洲基因分型市場分析 - 按最終用戶

  • 製藥和生物製藥公司
  • 診斷與研究實驗室
  • 學術機構
  • 其他最終用戶

第 11 章：歐洲基因分型市場 - 國家分析

    • 歐洲
      • 英國
      • 德國
      • 法國
      • 西班牙
      • 義大利
      • 歐洲其他地區

第 12 章：產業格局

  • 概述
  • 基因分型市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 13 章：公司簡介

  • Hoffmann-La Roche Ltd
  • QIAGEN NV
  • Merck KGaA
  • EUROFINS GENOMICS
  • Thermo Fisher Scientific Inc
  • BioTek Instruments, Inc.
  • Illumina Inc
  • Danaher Corp
  • Bio-Rad Laboratories Inc
  • GE HealthCare Technologies Inc
  • Standard BioTools Inc
  • Laboratory Corp of America Holdings
  • Beckman Coulter Inc
  • BGI
  • Takara Bio Inc
  • DiaSorin SpA

第 14 章：附錄

Product Code: BMIRE00025969

The Europe genotyping market was valued at US$ 8,729.90 million in 2023 and is expected to reach US$ 43,883.43 million by 2031; it is estimated to record a CAGR of 22.4% from 2023 to 2031.

Technological Advancements and Rising R&D Investments in Biotechnology and Pharmaceutical Industry Drives Europe Genotyping Market

Genotyping market players are focusing on increasing their investments in projects aimed at advancements in biotechnology to come up with better alternatives to conventional techniques.

In January 2024, Thermo Fisher Scientific launched Axiom PangenomiX Array, offering optimal genetic coverage for pharmacogenomic research and population-scale disease studies. This array is currently the only research solution that can run four assays in one test: SNP genotyping, complete genome copies number variant detection, fixed copy number discovery, and blood and HLA typing. In September 2023, Bio-Rad launched new PTC Tempo 48/48 and PTC Tempo 384 thermal cyclers for sequencing, cloning, and genotyping. The PTC Tempo thermal cyclers are built with an intuitive user interface and flexible connectivity features to streamline protocol management, along with monitoring capabilities on the cloud platform. In January 2023, Qiagen acquired Verogen, a company that uses next-generation sequencing (NGS) techniques to drive the future of forensic investigation and human identification (HID). QIAGEN and Verogen together are expected to create opportunities to help researchers advance forensic science, thereby aiding accurate suspect identification, finding missing persons, and exonerating innocent individuals. In June 2022, NRGene launched Soy SNPro, a product covered under predesigned SNP sets for genotyping (DNA tests) of various crops. SNPro is an off-the-shelf complete genotyping solution that combines low-density genotyping with high-density imputation. In May 2022, NEOGEN Corporation and Gencove announced the launch of InfiniSEEK, an innovative and cost-effective solution for addressing difficulties involved in whole-genome sequencing and targeted SNP analyses. Such technological breakthroughs have the potential to enable miniaturization, automation, and cost reduction. They can also aid in operational flexibility and multiparameter testing. All these benefits add to the uses and convenience of DNA sequencing, allowing clinicians to concentrate on higher-level decisions such as selecting and prioritizing therapeutic targets through various genotyping studies. Further, technological advancements in DNA sequencing, such as NGS, have enabled speedy, accurate sequencing, allowing for great productivity. Thus, the growing research and development activities, along with increasing government funding for genome-based projects, contribute to the genotyping market progress.

Europe Genotyping Market Overview

The Europe genotyping market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds the second-largest share of the global genotyping market and is expected to register a notable CAGR during the forecast period. Factors such as technological advancements, reducing prices of DNA sequencing procedures, increasing incidence of genetic diseases, and rising awareness of personalized medicine are among the factors aiding the growth of the Europe genotyping market .

Europe Genotyping Market Revenue and Forecast to 2031 (US$ Million)

Europe Genotyping Market Segmentation

The Europe genotyping market is categorized into product type, technology, application, end user, and country.

Based on product type, the Europe genotyping market is segmented into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment held the largest market share in 2023.

By technology, the Europe genotyping market is segmented into microarrays, capillary electrophoresis, sequencing, polymerase chain reaction (PCR), matrix-assisted laser desorption / MALDI-TOF, and other technologies. The polymerase chain reaction (PCR) segment held the largest market share in 2023.

Based on application, the Europe genotyping market is bifurcated into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and other applications. The diagnostics and personalized medicine segment held the largest market share in 2023.

In terms of end user, the Europe genotyping market is bifurcated into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and other end users. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the Europe genotyping market is segmented into the UK, Germany, France, Spain, Italy, and the Rest of Europe. Germany dominated the Europe genotyping market share in 2023.

Hoffmann-La Roche Ltd, QIAGEN NV, Merck KGaA, EUROFINS GENOMICS, Thermo Fisher Scientific Inc, BioTek Instruments Inc, Illumina Inc, Danaher Corp, Bio-Rad Laboratories Inc, GE HealthCare Technologies Inc, Standard BioTools Inc, Laboratory Corp of America Holdings, Beckman Coulter Inc, BGI, Takara Bio Inc, and DiaSorin SpA. are some of the leading companies operating in the Europe genotyping market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Europe Genotyping Market Landscape

  • 4.1 Overview
  • 4.2 Global Market Share Analysis
    • 4.2.1 Global Market Share (%) of Leading Players for NGS Library Preparation
    • 4.2.2 Global Market Share (%) of Leading Player for Genotyping
    • 4.2.3 Global Market Share (%) of Leading Player for Gene Expression

5. Europe Genotyping Market - Key Market Dynamics

  • 5.1 Market Drivers:
    • 5.1.1 Use in Diagnosis of Genetic and Rare Diseases
    • 5.1.2 Technological Advancements and Rising R&D Investments in Biotechnology and Pharmaceutical Industry
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Equipment and Shortage of Skilled Professionals
  • 5.3 Market Opportunities
    • 5.3.1 Expanding Range of Applications
  • 5.4 Future Trends
    • 5.4.1 Increasing Popularity of Personalized Medicine
  • 5.5 Impact of Drivers and Restraints:

6. Genotyping Market - Europe Analysis

  • 6.1 Genotyping Market Revenue (US$ Million), 2021-2031

7. Europe Genotyping Market Analysis - by Product Type

  • 7.1 Instruments
    • 7.1.1 Overview
    • 7.1.2 Instruments: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Reagents and Kits
    • 7.2.1 Overview
    • 7.2.2 Reagents and Kits: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Bioinformatics
    • 7.3.1 Overview
    • 7.3.2 Bioinformatics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Genotyping Services
    • 7.4.1 Overview
    • 7.4.2 Genotyping Services: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

8. Europe Genotyping Market Analysis - by Technology

  • 8.1 Microarray
    • 8.1.1 Overview
    • 8.1.2 Microarray: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Capillary Electrophoresis
    • 8.2.1 Overview
    • 8.2.2 Capillary Electrophoresis: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Sequencing
    • 8.3.1 Overview
    • 8.3.2 Sequencing: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Polymerase Chain Reaction (PCR)
    • 8.4.1 Overview
    • 8.4.2 Polymerase Chain Reaction (PCR): Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Matrix-Assisted Laser Desorption / MALDI-TOF
    • 8.5.1 Overview
    • 8.5.2 Matrix-Assisted Laser Desorption / MALDI-TOF: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Other Technologies
    • 8.6.1 Overview
    • 8.6.2 Other Technologies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Genotyping Market Analysis - by Application

  • 9.1 Pharmacogenomics
    • 9.1.1 Overview
    • 9.1.2 Pharmacogenomics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Diagnostics and Personalized Medicine
    • 9.2.1 Overview
    • 9.2.2 Diagnostics and Personalized Medicine: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Animal Genetics
    • 9.3.1 Overview
    • 9.3.2 Animal Genetics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Agricultural Biotechnology
    • 9.4.1 Overview
    • 9.4.2 Agricultural Biotechnology: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.5 Other Applications
    • 9.5.1 Overview
    • 9.5.2 Other Applications: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

10. Europe Genotyping Market Analysis - by End-user

  • 10.1 Pharmaceutical and Biopharmaceutical Companies
    • 10.1.1 Overview
    • 10.1.2 Pharmaceutical and Biopharmaceutical Companies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Diagnostic and Research Laboratories
    • 10.2.1 Overview
    • 10.2.2 Diagnostic and Research Laboratories: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Academic Institutes
    • 10.3.1 Overview
    • 10.3.2 Academic Institutes: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.4 Other End Users
    • 10.4.1 Overview
    • 10.4.2 Other End Users: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

11. Europe Genotyping Market - Country Analysis

  • 11.1 Europe Genotyping Market Overview
    • 11.1.1 Europe: Genotyping Market - Revenue and Forecast Analysis - by Country
      • 11.1.1.1 United Kingdom: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.1.1 United Kingdom: Genotyping Market Breakdown, by Product Type
        • 11.1.1.1.2 United Kingdom: Genotyping Market Breakdown, by Technology
        • 11.1.1.1.3 United Kingdom: Genotyping Market Breakdown, by Application
        • 11.1.1.1.4 United Kingdom: Genotyping Market Breakdown, by End-user
      • 11.1.1.2 Germany: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.2.1 Germany: Genotyping Market Breakdown, by Product Type
        • 11.1.1.2.2 Germany: Genotyping Market Breakdown, by Technology
        • 11.1.1.2.3 Germany: Genotyping Market Breakdown, by Application
        • 11.1.1.2.4 Germany: Genotyping Market Breakdown, by End-user
      • 11.1.1.3 France: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.3.1 France: Genotyping Market Breakdown, by Product Type
        • 11.1.1.3.2 France: Genotyping Market Breakdown, by Technology
        • 11.1.1.3.3 France: Genotyping Market Breakdown, by Application
        • 11.1.1.3.4 France: Genotyping Market Breakdown, by End-user
      • 11.1.1.4 Spain: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.4.1 Spain: Genotyping Market Breakdown, by Product Type
        • 11.1.1.4.2 Spain: Genotyping Market Breakdown, by Technology
        • 11.1.1.4.3 Spain: Genotyping Market Breakdown, by Application
        • 11.1.1.4.4 Spain: Genotyping Market Breakdown, by End-user
      • 11.1.1.5 Italy: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.5.1 Italy: Genotyping Market Breakdown, by Product Type
        • 11.1.1.5.2 Italy: Genotyping Market Breakdown, by Technology
        • 11.1.1.5.3 Italy: Genotyping Market Breakdown, by Application
        • 11.1.1.5.4 Italy: Genotyping Market Breakdown, by End-user
      • 11.1.1.6 Rest of Europe: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.6.1 Rest of Europe: Genotyping Market Breakdown, by Product Type
        • 11.1.1.6.2 Rest of Europe: Genotyping Market Breakdown, by Technology
        • 11.1.1.6.3 Rest of Europe: Genotyping Market Breakdown, by Application
        • 11.1.1.6.4 Rest of Europe: Genotyping Market Breakdown, by End-user

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in Genotyping Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Hoffmann-La Roche Ltd
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 QIAGEN NV
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Merck KGaA
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 EUROFINS GENOMICS
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Thermo Fisher Scientific Inc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 BioTek Instruments, Inc.
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Illumina Inc
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Danaher Corp
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Bio-Rad Laboratories Inc
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 GE HealthCare Technologies Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Standard BioTools Inc
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments
  • 13.12 Laboratory Corp of America Holdings
    • 13.12.1 Key Facts
    • 13.12.2 Business Description
    • 13.12.3 Products and Services
    • 13.12.4 Financial Overview
    • 13.12.5 SWOT Analysis
    • 13.12.6 Key Developments
  • 13.13 Beckman Coulter Inc
    • 13.13.1 Key Facts
    • 13.13.2 Business Description
    • 13.13.3 Products and Services
    • 13.13.4 Financial Overview
    • 13.13.5 SWOT Analysis
    • 13.13.6 Key Developments
  • 13.14 BGI
    • 13.14.1 Key Facts
    • 13.14.2 Business Description
    • 13.14.3 Products and Services
    • 13.14.4 Financial Overview
    • 13.14.5 SWOT Analysis
    • 13.14.6 Key Developments
  • 13.15 Takara Bio Inc
    • 13.15.1 Key Facts
    • 13.15.2 Business Description
    • 13.15.3 Products and Services
    • 13.15.4 Financial Overview
    • 13.15.5 SWOT Analysis
    • 13.15.6 Key Developments
  • 13.16 DiaSorin SpA
    • 13.16.1 Key Facts
    • 13.16.2 Business Description
    • 13.16.3 Products and Services
    • 13.16.4 Financial Overview
    • 13.16.5 SWOT Analysis
    • 13.16.6 Key Developments

14. Appendix

  • 14.1 About Us
  • 14.2 Glossary of Terms

List Of Tables

  • Table 1. Europe Genotyping Market Segmentation
  • Table 2. Genotyping Market - Revenue and Forecast to 2031 (US$ Million) - by Product Type
  • Table 3. Genotyping Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
  • Table 4. Genotyping Market - Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 5. Genotyping Market - Revenue and Forecast to 2031 (US$ Million) - by End-user
  • Table 6. United Kingdom: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 7. United Kingdom: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 8. United Kingdom: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 9. United Kingdom: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 10. Germany: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 11. Germany: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 12. Germany: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 13. Germany: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 14. France: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 15. France: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 16. France: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 17. France: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 18. Spain: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 19. Spain: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 20. Spain: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 21. Spain: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 22. Italy: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 23. Italy: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 24. Italy: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 25. Italy: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 26. Rest of Europe: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 27. Rest of Europe: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 28. Rest of Europe: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 29. Rest of Europe: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 30. Recent Organic Growth Strategies in Genotyping Market
  • Table 31. Recent Inorganic Growth Strategies in the Genotyping Market
  • Table 32. Glossary of Terms, Genotyping Market

List Of Figures

  • Figure 1. Europe Genotyping Market Segmentation, by Country
  • Figure 2. Genotyping Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Genotyping Market Revenue (US$ Million), 2021-2031
  • Figure 5. Genotyping Market Share (%) - by Product Type (2023 and 2031)
  • Figure 6. Instruments: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Reagents and Kits: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Bioinformatics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Genotyping Services: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Genotyping Market Share (%) - by Technology (2023 and 2031)
  • Figure 11. Microarray: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Capillary Electrophoresis: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Sequencing: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Polymerase Chain Reaction (PCR): Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Matrix-Assisted Laser Desorption / MALDI-TOF: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Other Technologies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Genotyping Market Share (%) - by Application (2023 and 2031)
  • Figure 18. Pharmacogenomics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Diagnostics and Personalized Medicine: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Animal Genetics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Agricultural Biotechnology: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Other Applications: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Genotyping Market Share (%) - by End-user (2023 and 2031)
  • Figure 24. Pharmaceutical and Biopharmaceutical Companies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Diagnostic and Research Laboratories: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Academic Institutes: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Other End Users: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. Europe Genotyping Market, by Key Countries - Revenue (2023) (US$ Million)
  • Figure 29. Europe: Genotyping Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 30. United Kingdom: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. Germany: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. France: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Spain: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. Italy: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 35. Rest of Europe: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 36. Growth Strategies in Genotyping Market